Masahiro Morise (Masahire Morise)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Tyrosine Kinase

Ejection Fraction

Top Venues

Future oncology (London, England)

Journal of ultrasonography

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Takako Inoue, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Eisuke Horii, Svenja Adrian, Rolf Bruns, Andreas Johne, Paul K Paik, Hiroshi Sakai
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science 115 (4) (2024)
Shotaro Okachi, Toshinori Matsui, Manami Sakurai, Takayasu Ito, Masahiro Morise, Kazuyoshi Imaizumi, Makoto Ishii, Michitaka Fujiwara
Real-time ultrasound-guided thoracentesis simulation using an optical see-through head-mounted display: a proof-of-concept study. Journal of ultrasonography 24 (96) (2024)
Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Takako Inoue, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Eisuke Horii, Svenja Adrian, Rolf Bruns, Andreas Johne, Paul K Paik, Hiroshi Sakai
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science 115 (4) (2024)
Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Takako Inoue, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Eisuke Horii, Svenja Adrian, Rolf Bruns, Andreas Johne, Paul K Paik, Hiroshi Sakai
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science (2024)
Shotaro Okachi, Toshinori Matsui, Manami Sakurai, Takayasu Ito, Masahiro Morise, Kazuyoshi Imaizumi, Makoto Ishii, Michitaka Fujiwara
Real-time ultrasound-guided thoracentesis simulation using an optical see-through head-mounted display: a proof-of-concept study. Journal of ultrasonography 24 (96) (2024)
Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Takako Inoue, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Eisuke Horii, Svenja Adrian, Rolf Bruns, Andreas Johne, Paul K Paik, Hiroshi Sakai
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science 115 (4) (2024)
Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Takako Inoue, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Eisuke Horii, Svenja Adrian, Rolf Bruns, Andreas Johne, Paul K Paik, Hiroshi Sakai
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science 115 (4) (2024)
Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Takako Inoue, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Eisuke Horii, Svenja Adrian, Rolf Bruns, Andreas Johne, Paul K Paik, Hiroshi Sakai
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science 115 (4) (2024)
Naoyuki Nogami, Atsushi Nakamura, Naoko Shiraiwa, Hironori Kikkawa, Birol Emir, Robin Wiltshire, Masahiro Morise
Effectiveness of crizotinib in patients with ROS1 -positive non-small-cell lung cancer: real-world evidence in Japan. Future oncology (London, England) (2023)
Akito Hata, Isamu Okamoto, Naoki Inui, Morihito Okada, Masahiro Morise, Kohei Akiyoshi, Masayuki Takeda, Yasutaka Watanabe, Shunichi Sugawara, Naofumi Shinagawa, Kaoru Kubota, Toshiaki Saeki, Tomohide Tamura
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Li, Julien Mazieres, Soon Hin How, Masahiro Morise, Viola W Zhu, Daniel Shao-Weng Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance. Future oncology (London, England) 18 (9) (2021)